ReviewCell death discovery2025
Mesenchymal stem cells for lung diseases: focus on immunomodulatory action.
Review in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Safety, feasibility, and exploratory biomarker findings of bone marrow-derived mesenchymal stromal cells in hospitalized severe COVID-19: a phase I/II randomized trial.Journal of thoracic disease · 2026Article
- Mesenchymal stem/stromal cell-based therapies for autism spectrum disorder: emerging evidence and clinical prospects.Journal of translational medicine · 2026Review
- Mesenchymal Stem Cells Derived Extracellular Vesicles in Inflammatory Bowel Disease: Therapeutic Efficacy and Bioengineering Applications.International journal of nanomedicine · 2026Review
- Pulmonary vascular dysfunction in ARDS Pathophysiology and therapeutic implications.Annals of intensive care · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the morbidity and mortality caused by acute and chronic lung diseases have gradually increased, becoming a global public health burden. However, modern medicine has yet to determine the exact treatment for lung diseases associated with inflammation. Alleviating lung diseases and repairing injured lung tissue are urgent issues that need to be resolved. Mesenchymal stem cells (MSCs) have been used to treat various inflammatory diseases owing to their powerful anti-inflammatory, anti-apoptotic, and tissue-regenerative properties. MSCs show great promise and have been shown to play a role in relieving lung diseases experimentally. The immune regulatory role of MSCs is thought to be a key mechanism underlying their multiple potential therapeutic effects. Immune cells and secreted factors contribute to tissue repair following lung injury. However, the overactivation of immune cells can aggravate lung injury. Here, we review evidence that MSCs act on immune cells to relieve lung diseases. Based on the immunomodulatory properties of MSCs, the specific mechanisms by which MSCs in alleviate lung diseases are reviewed, with a focus on innate and adaptive immunity. In addition, we discuss current challenges in the treatment of lung diseases using MSCs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.